Q-omics provides the consensus-scored TEKT5 profile across patient tissues and cancer cell-line models. TEKT5 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TEKT5 is differentially expressed in 8, with the highest sampling consensus in LUAD. Additionally, TEKT5 RNA expression shows 11,677 significant gene co-expression associations, with the highest sampling consensus in BLCA. Together, these results highlight KIRC, LUAD, and BLCA as cancer lineages where TEKT5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TEKT5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TEKT5 survival associations across molecular data types. TEKT5 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TEKT5 RNA expression–survival associations across cancer types. High TEKT5 expression shows unfavorable associations in KIRC, THCA, KIRP and ACC, but favorable associations in BLCA and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TEKT5 RNA expression.
This table summarizes TEKT5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for TEKT5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TEKT5 shows higher tumor expression in LUAD, LIHC, BRCA, UCEC, KIRC and CHOL. The LUAD box plot shows higher TEKT5 RNA expression in tumor versus normal tissue (log2 FC = +0.418, t-test p < 0.001).
This table shows molecular features associated with TEKT5 in patient tissues and cancer cell lines. In patient samples, TEKT5 shows the broadest associations at the RNA and protein expression levels, with BLCA recurring as the lineage with the largest associated feature set. In cancer cell lines, TEKT5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
